Literature DB >> 7039629

Association between endogenously activated T cells and immunoglobulin-secreting B cells in patients with active systemic lupus erythematosus.

P L Cohen, D A Litvin, J B Winfield.   

Abstract

Systemic lupus erythematosus (SLE) is characterized by increased numbers of circulating B cells activated polyclonally to secrete immunoglobulin. Because T cells secrete, or shed, various factors that are functionally important in regulating immunoglobulin production by B cells, a reverse hemolytic plaque assay was developed to quantitate such activated T cells. In this technique, we used a rabbit antiserum raised to supernatants of concanavalin-A--stimulated human lymphocytes. The relevant antigenic specificity of this antiserum is directed toward the shed surface membrane determinant(s) preferentially expressed on activated T cells. Freshly isolated peripheral blood mononuclear cells from 14 SLE patients contained more than 10 times the number of endogenously activated T cells than cells from normal subjects. Within the SLE group, plaque-forming T cells were particularly increased in patients with active disease. By linear regression analysis, a significant positive correlation was revealed between such activated T cells and immunoglobulin-secreting B cells, also measured by a reverse plaque assay (r = 0.83). It appears that both activated B cells and T cells circulate in increased numbers in SLE. Additional investigation will be required to define the molecular nature of the T cell product(s) being measured and to clarify the relationship of these findings to the immunoregulatory abnormalities in this disorder.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039629     DOI: 10.1002/art.1780250209

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Heterogeneity of RNP and Sm autoantigens in relation to the cell sources and the activated state of the cells.

Authors:  F Hiepe; K Yamamoto; A Takeuchi; E Apostoloff; T Miyamoto
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  T lymphocyte activation in systemic lupus erythematosus analysed by proliferative response to nucleoplasmic proteins on nitrocellulose immunoblots.

Authors:  B N Pham; L Prin; D Gosset; P Y Hatron; B Devulder; A Capron; J P Dessaint
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Accessory cell activity of monocytes in anti-DNA antibody production in systemic lupus erythematosus.

Authors:  T Sasaki; S Shibata; Y Hirabayashi; Y Sekiguchi; K Yoshinaga
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

4.  The influence of interferon-gamma, interleukin-2, prostaglandin E2, and cyclosporine on the polyclonal and anti-DNA antibody secretion in lymphocyte cultures derived from patients with systemic lupus erythematosus.

Authors:  H D Volk; N Sönnichsen; S Jahn; F Hiepe; E Apostoloff; R von Baehr; W Diezel
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

5.  Nature of IgG anti-lymphocyte autoantibody-reactive molecules shed from activated T cells in systemic lupus erythematosus.

Authors:  S Minota; J B Winfield
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

7.  Studies of the pathogenesis of angioimmunoblastic lymphadenopathy.

Authors:  M Honda; H R Smith; A D Steinberg
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells.

Authors:  M Linker-Israeli; A C Bakke; F P Quismorio; D A Horwitz
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

9.  IL-2 normalizes defective suppressor T cell function of patients with systemic lupus erythematosus in vitro.

Authors:  H D Volk; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

10.  Inhibition of soluble antigen-induced T cell proliferation by warm-reactive antibodies to activated T cells in systemic lupus erythematosus.

Authors:  A Yamada; J B Winfield
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.